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Abstract: Prevention of Hemoglobinopathies has developed around the world based upon the 
experience  done  in  pioneering  endemic  countries  and  is  now  facing  a  new  phase  in  non-
endemic areas with a recent immigration history. We describe two situations, taking Latium 
(central Italy) and The Netherlands as two models for endemic and non-endemic countries 
both confronted with a large multi-ethnic immigrant society. We present prevention results 
and discuss aspects such as local knowledge and organization. We illustrate the importance of 
issues like information, carrier diagnostics, screening, counseling and prenatal diagnosis in 
particular  situation  of  contrasting  interest  an  different  ethical  opinions.  We  conclude  by 
underlining the importance of implementing primary prevention at the European level, based 
upon better information, diagnostics and counseling. 
Introduction: Hemoglobinopathies (HbP’s) are the 
most common recessive autosomal disorders in man 
because  carriers  are  protected  against  child 
mortality  due  to  malaria.  This  advantage  has 
strongly  selected  the  traits  in  all  tropic  and  sub-
tropic areas of the old world were most carriers live 
today.  However,  due  to ancient  and  recent 
migrations  HbP’s  are  now  present  virtually 
everywhere  including  those  non-endemic 
industrialized  areas  where  people  from  endemic 
countries migrate in search of work. 
Severe  Hemoglobinopathies  (Thalassemia  and 
Sickle  Cell  Disease)  are  conditions  affecting  our 
oxygen transport protein hemoglobin A (HbA). This 
tetramer consists of 4 globin chains (α2/β2) coded 
by  genes  located  on  chromosome  16  (the  alpha 
genes)  and  11  (the  beta  genes).  While  β-
Thalassemia  is  caused  by  defects  impairing  the 
expression  of  the  β  globin  genes,  Sickle  Cell 
Disease  (SCD)  is  induced  by  a  single  β-gene 
mutation  (HbS),  either  in  homozygous  form 
(HbS/S)  or  in  a  number  of  common  compound 
heterozygous  conditions  such  as  HbS/β-thal,  
HbS/C, HbS/D,  HbS/E and others.  
The  WHO  has  been  recommending  primary 
prevention  for  many  years  because  these  severe 
diseases,  although  treatable,  cannot  be  “cured” 
unless  a  bone  marrow  transplant  is  successfully 
performed. Therefore primary prevention has been 
offered for the last 30 years  to couples at risk in the Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Mediterranean  area  where  the  incidence  of  β-
Thalassemia  major  in  pioneering  countries  like 
Cyprus,  Italy  and  Greece  has  been  reduced  to 
almost zero 
1-3. 
Preface. To day also non-endemic countries are in 
urgent  need  of  prevention  because  immigrant 
couples from endemic countries usually do not mix 
with Northern European, make more children than 
average and  often with a consanguineous partner. 
All this keeps the chance of getting a child affected 
by  SCD  or  Thalassemia  major  as  high  as  in  the 
country of origin
4.
In the  UK, dedicated colleagues were the first 
who  succeeded  building up  prevention  campaigns 
and to date neonatal screening and early pregnancy 
diagnostic  is  available  in  this  country  where  the 
expected  incidence  of  the  severe  conditions  is 
significantly reduced
5. 
In other developed Western European countries 
with large immigrant populations this problem has 
been neglected for a long time. Only by the turn of 
the  century  public  health  authorities  started  to 
realize  that  prevention  had to  be  offered  to  these 
growing  communities  but  with  the  exception  of 
Belgium, Northern France and The Netherland, no 
other continental regions of North European have 
started  offering  organized  prevention  options  as 
yet
6.
In The Netherlands in particular only a modest 
incidence reduction has been achieved thus far in 
spite of substantial efforts in different directions and 
the implementation of newborn screening (NBS) in 
2007
7. In this country only few couples at risk reach 
prospective  prevention  after  they  have  been 
properly  informed  and  virtually  none  of  those 
couples identified during NBS because they had an 
affected child has reached a genetic center thus far
8.   
In contrast, the Thalassemia prevention program 
applied  in  the  Latium  region,  the  earliest  ever 
planned and introduced in Italy by Silvestroni and 
Bianco in the early 60
2, can be considered as the 
most  successful.  Since  1993,  prospective  primary 
prevention (offered to couples at risk diagnosed and 
informed before their first pregnancy) was virtually 
total,  reducing  the  expected  incidence  of 
Thalassemia  major  to  virtually  zero  in  the  native 
population.  However, due to the many immigrants 
from  endemic  countries  that  are  not  reached  by 
information and carrier diagnostics, new problems 
are arising in Latium as well.  The situations both in 
Latium and in The Netherlands  were described as 
two models for endemic and non-endemic countries.
Methods:  Information  and  carrier  diagnostics  are 
the  key  elements  of  prevention.  The  moment  of 
intervention  is  crucial  and  the  sooner  carriers  are 
detected the better it is for their prevention choices. 
However, while early, premarital or preconception 
diagnostics  is  offered  in  endemic  countries,  non-
endemic  immigration  countries  have  implemented 
NBS  and  retrospective  prevention  for  parents  of 
affected children is depending from the advice of 
pediatricians who may or may not decide to inform 
the  parents  about  prevention  or  may  or  may  not 
refer them to genetic centers.   
The  Latium  prevention  program.  The  long 
established  prevention  campaign  consists  of a 
focused biology lesson and universal screening for 
all pupils attending secondary school. The spin off 
of  this  screening  consists  of  information  of  the 
parents,  carrier  diagnostics  of  parents  and  family 
and registration on a data base. Carrier’s follow up 
concern  pre-matrimonial  or  pre-conception 
diagnostics,  identification  of  couples  at  risk  and 
genetic  counseling,  carrier  diagnostics  in  early 
pregnancy  and  prenatal  diagnosis  after  informed 
decision.  Due  to  the  rise  of incidence  among 
immigrants  the  information  campaigns  has  been 
intensified  in  order  to  reach  the  immigrant 
population.
The  Dutch  prevention  attempts.  Prenatal 
diagnosis has been available in the countries from 
the late 80thies at Leiden reference centre but no 
prevention campaigns are available. Therefore, all 
laboratories in the countries have been enquired and 
instructed how to perform basic carrier diagnostics 
and how to advice control of parents, partner and 
sibs,  or  the  younger  generation  when  a  infant,  a 
young  or  an  elderly  carrier  have  been  diagnosed, 
respectively.  However,  to  perform  carrier 
diagnostics  one  needs  a  doctor  prescription, 
Therefore,  many  post  academic  teaching  courses 
and  at  least  one  publication  a  year  has  been 
dedicated  to  enduring  education  of  general 
practitioners and midwifes over the last 10 years. 
Explanatory and reassuring letters, addressed to the 
healthy  carriers,  explaining  the  importance  of 
prevention,  have  been  used  for  all  patients 
diagnosed at the reference centre. First pregnancy 
control has been offered in a pilot setting and is now 
implemented in the city of Gouda and is on his way 
to  implementation  in  the  city  of  The  Hague. 
Neonatal  screening  has  started  in  2007.  Affected 
children  are  referred  to  dedicated  pediatricians  in 
academic  centers  but  referral  of  the  parents  to Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
genetic  centers  remains  sporadic.  Carrier 
diagnostics  in  the  preconception  phase  is  slowly 
growing,  mainly  based  upon  medical  indication 
(anemia).    Carrier  diagnostics  based  upon  ethnic 
origin is depending from the initiative of informed 
GP’s eventually responding (or not) to the request 
of informed patients.
Technical methods. Carrier diagnostic methods are 
state of the art protocols in both centers. The simple 
visual  single  tube  osmotic  fragility  test
9 and  the 
erythromorphology  evaluation  are  applied 
systematically  during  school  screening  for 
Thalassemia in Latium and are part of the carrier 
diagnostic  protocol  at  Leiden  Reference  Center, 
together  with  the  measurement  of  standard 
hematological  parameters  on  automatic  counters. 
Both in Latium and The Netherlands separation and 
estimation  of  the  hemoglobin  fractions,  either  on 
alkaline  electrophoresis  or  on  capillary  electro-
phoresis  (Capillarys,  Sebia  France)  and  on  High 
Performance  Liquid  Chromatography  (HPLC),  is 
done  using  different  dedicated  devices  among 
which  the  HPLC  VARIANT  II™  (Bio-Rad 
Laboratories,  Hercules,  CA,  USA),  the  HA  8160 
(Menarini,  Florence,  Italy)  or  the  Capillay 
Electrophoresis  device  (Sebia,  Paris  France)  as 
described  elsewhere
10. Ferritin  or  zink  proto-
porphirine are measured when needed to  evaluate 
iron deficiency. 
Molecular  analysis  is  performed  in  both  labs, 
either routinely or when needed. Genomic DNA is 
isolated  by  salt-extraction  and  point  mutation 
analysis  of  the   globin  gene is  done  by  direct 
sequencing using commercial devices (ABI Prism, 
USA). Complex cases are  studied by globin chain 
synthesis 
11 and eventually in collaboration 
12.
Results
Latium: In the  period 2002-2007, 13.597 foreign 
pupils from 140 different nations, representing the 
8.2% of the secondary school population (age 13) 
were investigated and screened regularly each year. 
After explaining that school screening is a way to 
detect healthy carriers and, in due time, couples at 
risk,  69.4%  of  the  parents  responded  in  favor  of 
prevention  sharing  the  information  with  their 
relatives.  Screening  compliance  in  immigrants 
families  (64%)  was  higher  than  among  Italians 
showing  that  this  initiative  is  not  felt  as  a 
stigmatizing issue. 
Between  1994  and  2008  a  total  of  180,477 
individuals were examined at the Ambulatory Care 
Clinic for carrier diagnostics. The share of foreign 
subjects visiting our structure has increased in this 
period from 2.7% in 1994, to 9.74% in 2008.
We  have  found  8,826  foreign  individuals  non 
carriers  (of  which  2,766  were  iron  deficient  and 
6,060 normal) and 2,917 carriers or affected. In the 
last  cohort    22.2%  were  -thalassemia  carriers, 
50.25%  were  suspected  -thalassemia  carriers, 
13.06%  were  HbS,  3.7%  HbE,  and  1.64%  HbC 
carriers,  while  4.18%  were    carriers  of  rare  Hb 
variants  and  4.97%  were  affected  with  severe 
conditions  deriving  from  associations  with  HbS, 
HbC,  HbE,  -thalassemia  (HbH  disease)  and  β-
thalassemia  mutations  uncommon  in  the  native 
Italian population. 
In  spite  of  these  efforts,  the established 
prevention program does not reach all immigrants 
and the incidence of non indigenous affected people 
has  increased.  Since  2000  practically  all  affected 
children  are  from  recent  immigrants.  The  few 
patients of Italian origin born after 1994 are from 
well informed couples at risk who refused prenatal 
diagnosed as a consequence of a personal choice. 
Data are shown in Figure 1.
The  Netherlands: Although  compared  with  10 
years  ago  the  improvement  is  substantial, 
prevention is still blocked at several bottlenecks in 
The Netherlands. 
Most  laboratories  in  the  country  are  able  to 
provide basic carrier diagnostics 
13 but GP’s are still 
not  controlling  their  foreign  clients  routinely. 
Referral for carrier diagnostics is eventually done 
based upon a diagnostic protocol published by the 
Dutch  GP’s  organization  advising  control  when 
anemia  persists  after  iron  therapy
14.  Of  course 
following this protocol most carriers of HbS, C, ad 
D will remain undiagnosed unless dedicated GP’s 
will  refer  upon  ethnic  indication.  Unfortunately, 
control upon ethnic indication is not yet officially 
advised  by  the  GP’s  organization,  while  it  is  for 
diabetes screening in people of Hindu origin
15.  
It can be estimated that all together no more than 
6.000 analyses for carrier diagnostics are annually 
requested in this way in the country. Considering 
the natural incidence and the number of demands 
for prenatal diagnosis, less then 10% prevention has 
been reached in The Netherlands thus far, meaning 
that  every  year  about  230  couples  at  risk  do  not 
reach information and miss their chance to choose 
for prevention.  Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 1. The graph compares the number of affected Italian and foreign patients diagnosed at CSMR for the first time between 1994 
and 2008.    The rate of   foreign increases while the  incidence of the  Italians  currently  declines  as a consequence  of intensive 
education. Adapted from Amato et al submitted to Prenatal Diagnosis 2009.
The National Public Health Council has recently 
advised more research on preconception screening 
based on ethnic origin while recently a study at the 
theoretical level has proposed a strategy based on 
ethnic  origin  for  combined  carrier  screening  of 
Cystic Fibrosis (CF) and Hemoglobinopathy
16, this 
in  spite  of  the  fact  that  technology  and  financial 
effort are totally different.   
Early pregnancy control is the  most promising 
initiative. Dedicated midwifes who are taking good 
care of their clients, advise carrier diagnostics. Pilot 
studies have been published
17 and other pilot studies 
are  ongoing  hopefully  leading  soon  to  a  new 
standard national protocol.
Newborn  screening  (NBS)  has  started  on 
January 1
st 2007, analyzing near  200.000 samples 
per year in the same 5 labs which are screening for 
metabolic diseases. The method of choice (HPLC) 
was  tested  at  the  reference  lab  in  Leiden
18 and 
validated  in  2006  in  2  screening  laboratories
19-20. 
The  method detects at  100% sensitivity SCD and 
TM  and  all  kind  of  carriers  including  alpha 
thalassemia with elevated Hb Bart’s. Nevertheless, 
the majority of the TM cases was missed during the 
first 2 years because some labs went on considering 
1-2%  HbA  normal  in  non  premature  newborn 
(Normal  +/- 20%)  and  did  not  feed  back  their 
results to the reference lab. Meanwhile, incidence 
figures  have  been  prematurely  published with  a 
large  underestimation  for  TM
21 while  an  internal 
discussion is ongoing whether or not to report high 
HbBart’s and at which level. 
In  spite  of  all  that,  the  system  is  technically 
sound  and  the  predicted  incidence  of  at  least  60 
affected  children  per  year  was  found
22.  
Unfortunately,  couples  at  risk,  counseled  by 
pediatricians have totally disregarded prevention so 
far
8, while enquiries among local parents of affected 
children  have  long  proved  that  prevention  is 
welcome  in  more  than  80%  of  the  cases  in  The 
Netherlands
23. Carriers of HbS, C, E, D, O, etc… 
should be reported for primary prevention of serious 
Hemoglobinopathies.  Unfortunately  only  HbS 
carriers have been reported so far, also when parents 
have  chosen  to  be  fully  informed.  GP’s  receive 
insufficient  and unclear information regarding the 
NBS results and the actions to be taken. Therefore 
they confuse trait with disease and refer parents of 
HbS  carriers  to  genetic  centers  making  them 
unnecessarily  worried  before  any  risk  is  proved. 
Because of these starting problems, some consider 
carrier detection “unwanted byproducts” that should 
not be reported and would prefer to have a method 
that  detects  patients  only.  On  the  contrary,  other 
think that carriers report should be considered also 
for other diseases. School screening is not available Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 2. Prospective (grey columns) versus retrospective prevention (black columns) among indigenous couples at risk (left) and 
immigrant couples (right). Among immigrant couples the prevention it is still largely retrospective, while for Italian couples is fully 
prospective from 1993. Adapted from Amato et al submitted to Prenatal Diagnosis 2009.
in the country but should be considered as soon as 
possible, especially in the large cities.
Discussion
Latium: In  spite  of  the  good  results  in  offering 
prospective prevention to the indigenous population 
(100%  from  1994)  the  prevention  for  foreign 
couples at risk have been also in Latium mainly of 
the  retrospective  type  so  far  (70%).  Out  of  60 
foreign  couples  at risk  counseled,  42  had 
retrospectives prevention after at least one affected 
child was born and only 18 couples had no affected 
child at the moment of identification. In spite of that 
our results show that by improving the information 
campaigns for the immigrant population prospective 
prevention  is  possible  also  among  recent 
immigrants (Figure 2). 
The Netherlands: The Netherlands has neglected 
primary  prevention  for  the  growing  ethnic 
minorities until the turn of the century 
24 and have 
started to give some attention to the problem only 
after an enduring process of persuasion 
25-30.
Unfortunately,  initiatives  have  not  been 
primarily focused on the implementation of primary 
prevention strategies and in the end the only official 
initiative so far (NBS) was taken to provide early 
treatment  as  it  is  the  case  for  Phenylketonuria 
(PKU).  This  while  these  patients  do  not  need 
treatments shortly after birth, but from 6 months on 
and therefore do not need to be universally screened 
at  birth  but  could  be  better  selectively  diagnosed 
during the first semester of life based on the ethnic 
origin  if  the  GP’s  would  be  available  to  do  that 
(which is not the case at the moment). 
Moreover,  the  NBS  advisory  commission  is 
composed  mainly  by  pediatricians,  mainly 
interested in early treatment and much less in carrier 
analysis  and  prevention.  Contrasting  interests  are 
often discussed using ethical concepts, heritage of 
the  conservative  politic  of  the  80thies,  based  on 
confusions between recessive traits  and late onset 
dominant  genetic  diseases.  Reasonable  in  the  last 
case,  the  right  to  refuse  (genetic)  information  is 
improperly applied to the carriers of recessive traits, 
claiming  that  healthy  carriers  could  possibly  get 
worried  by  genetic  information  and  that  minors 
should  not  be  informed  until  the  age  of  18, 
overlooking  that  in  NBS  is  not  the  newborn  that 
gets  the  information  but  the  responsible  parents. 
Under these circumstances primary prevention as a 
spin  off  of  from  NBS  has  become  a  tormented 
history in The Netherlands. 
An official implementation of carrier diagnostics 
in  preconception  of  early pregnancy  phase,  could 
also  run  the  risk  to  become  a  matter  of  a  long 
discussion  if  considered  as  a  national  screening. 
Therefore, carrier analysis should not be considered 
as a screening to be approved by politics but as a 
regular  diagnostic  procedure  for  which  the  only 
approval needed is the one of the informed patient 
and for which the indication could be a medical one 
or just the ethnic origin from a high prevalence area. 
Therefore it is essential to have informed patients 
requiring carrier diagnostics to informed GP’s and 
informed labs able to provide the analysis and an 
explanatory letter.
Information. It seems evident from our paper that, 
beside  politics,  information  remains  the main 
problem when implementing prevention strategies. 
When properly provided, information is providing 
knowledge  and  is  not  producing  anxiety  or 
stigmatization  to  ethnic  minorities.  Therefore 
information needs to be offered in a better way and 
to be adapted to the different cultural situations. Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Information in endemic countries is directed to 
the whole of the population, is better understood, is 
provided  by  doctors  aware  of  the  situation  and 
nobody is stigmatized. Information in non-endemic 
countries  provided  by  public  campaigns  may 
stigmatize  immigrants  and  should  therefore  be 
delivered  privately  by  an  educated  general 
practitioner who does not confuses trait with disease 
and  by  pediatrician  that,  beside  treating  affected 
children  in  the  best  possible  way, should  refer 
couples at risk to genetic centers. 
A  comprehensive  and  reassuring  letter  to  the 
diagnosed carrier, to be discussed with the family 
doctor, is in our experience a way to prevent anxiety 
and  provide  correct  information  to  carriers  and 
professional knowledge to the unaware GP. Such a 
letter  is  a  task  for  the  experienced  laboratory 
providing the diagnosis, both in endemic and non 
endemic  countries.  Counseling  may  need  some 
cultural  adaptation.  However  the  fundamental 
elements  of  counseling  that  can  be  used  in  all 
cultures are that i) being carriers is not a disease, ii) 
that  carriers will not  develop the  disease later  on 
and iii) that knowing which of the recessive traits 
we carry is an advantage that allows partner control 
and the prevention of severely affected children. 
Conclusion. Prevention should be encouraged and 
financially  supported  at  the  European  level. 
Prevention  should  be  introduced  based  on  the 
experiences  made  both  in  the  pioneering  and  in 
immigration  countries,  both  confronted  with 
newcomers, new mutations, new languages and new 
cultures. Improved information should be provided 
there  where  immigrants  do  not  reach  prevention 
through the local information channels. If we do not 
intervene  properly  at  the  European  level  more 
severely  affected  children  will  be  born,  having 
inherited a trait from two healthy parents who have 
not been informed and who otherwise would have 
probably chosen for prevention. 
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